Baird raised the firm’s price target on DexCom to $153 from $145 and keeps an Outperform rating on the shares. The firm said with this quarter’s upside coming despite a “nominal” initial domestic contribution from basal-only, DexCom’s competitive share gains in international markets are clearly continuing, and 2Q another quarter of record new patient starts globally, Baird believes the path to additional beats/raises remains well-defined for the company.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DXCM: